Hilleman licenses Oral Cholera Vaccine to Bharat Biotech

Collaboration seeks to strengthen the ability to prevent cholera

Davinder Gill, chief executive officer of Hilleman Laboratories with Krishna Ella, chairman and managing director of of Bharat Biotech
Davinder Gill, chief executive officer of Hilleman Laboratories with Krishna Ella, chairman and managing director of of Bharat Biotech

Hilleman Laboratories, a global research and development organization focused on delivering high-impact and affordable vaccines, announced that it has entered into a collaboration with Bharat Biotech International Ltd (BBIL), a leading vaccine and biotechnology company in India, for further development, manufacturing and commercialization of its next-generation Oral Cholera Vaccine, Hillchol. This collaboration will strengthen the ability of both organizations towards prevention of cholera through rapid and cost-effective deployment of vaccine doses in low and middle-income countries.

Cholera is an acute diarrheal infection caused by Vibrio Cholerae and has been responsible for seven pandemics till date. A poverty-related endemic in South Asia and Africa, cholera is on the WHO priority list. Globally, cholera accounts for ~2.8 million cases and an estimated 95,000 deaths annually. In India, about 30% of the population (375 million people) remain at risk. Deployment of oral cholera vaccines (OCVs) are an essential public health component of comprehensive cholera prevention and control, recommended by the WHO and an element of its ‘End Cholera’ initiative.

Hillchol was designed at the University of Gothenburg in Sweden and subsequently developed by Hilleman Labs including demonstration of safety and immunogenicity in an age deescalating Phase I and II clinical trial conducted in Bangladesh with the assistance of icddr, b and Incepta Vaccines. For further development of Hillchol, Hilleman Labs has entered into a licensing and manufacturing agreement with BBIL, who will scale the manufacturing process to commercial stage and establish product specifications required for WHO pre-qualification.

Jan Holmgren, professor, University of Gothenburg who along with his colleague Michael Lebens and their team invented the vaccine commented, “Hillchol contains a single recombinant Hikojima strain which expresses both Inaba and Ogawa antigens, resulting in a shorter and simpler manufacturing process as compared to licensed OCVs. Hillchol will therefore be of great importance and value to help to meet the urgent demands from cholera-afflicted countries for much expanded oral cholera vaccines manufacturing and supplies for the control of cholera globally.”

Speaking about the partnership, Davinder Gill, chief executive officer, Hilleman Laboratories said, “Vaccines play a critical role in improving healthcare outcomes globally, and Hilleman Laboratories is honored to work with Bharat Biotech, a leading vaccine manufacturer in India for development, and if licensed, eventual manufacturing and commercialization of our innovative oral cholera vaccine Hillchol. Availability of an affordable cholera vaccine is particularly significant considering that more than 50 GAVI eligible countries have been categorized as cholera-endemic. We hope this collaboration will provide an innovative vaccine solution which is both affordable and accessible.”

Krishna Ella, chairman and managing director of Bharat Biotech International said, “We are delighted to lead the scale-up, development, manufacturing and commercialization efforts for Hillchol with our collaboration marking an important step. Our capacity to deliver 50 million doses per year and the addition of a WHO pre-qualification of Hillchol in the future, will not only solve the demand uncertainty but aid in affordability thereby resulting in the wider use of such a vital oral cholera vaccine worldwide.”

Gerd Zettlmeissl, chairman, Hilleman Laboratories congratulated both partners on entering into a collaboration agreement to align efforts and said, “By working together, we can move even closer to meeting the critical public health goal of reducing cholera burden by 90% by 2030, a key objective of WHO End Cholera initiative.”

The impact, resilience, and growth of responsible packaging in a wide region are daily chronicled by Packaging South Asia.

A multi-channel B2B publication and digital platform such as Packaging South Asia is always aware of the prospect of new beginnings and renewal. Its 16-year-old print monthly, based in New Delhi, India has demonstrated its commitment to progress and growth. The Indian and Asian packaging industries have shown resilience in the face of ongoing challenges over the past three years.

As we present our publishing plan for 2023, India’s real GDP growth for the financial year ending 31 March 2023 will reach 6.3%. Packaging industry growth has exceeded GDP growth even when allowing for inflation in the past three years.

The capacity for flexible film manufacturing in India increased by 33% over the past three years. With orders in place, we expect another 33% capacity addition from 2023 to 2025. Capacities in monocartons, corrugation, aseptic liquid packaging, and labels have grown similarly. The numbers are positive for most of the economies in the region – our platform increasingly reaches and influences these.

Even given the disruptions of supply chains, raw material prices, and the challenge of responsible and sustainable packaging, packaging in all its creative forms and purposes has significant headroom to grow in India and Asia. Our context and coverage engulf the entire packaging supply chain – from concept to shelf and further – to waste collection and recycling. We target brand owners, product managers, raw material suppliers, packaging designers and converters, and recyclers.

In an admittedly fragmented and textured terrain, this is the right time to plan your participation and marketing support communication – in our impactful and highly targeted business platform. Tell us what you need. Speak and write to our editorial and advertising teams! For advertisement ads1@ippgroup.in , for editorial info@ippgroup.in and for subscriptions subscription@ippgroup.in

– Naresh Khanna

Subscribe Now
unnamed 1


Subscribe to our Newsletter

As 2023 begins and FY 23-24 unfolds, will you support us?

What lies in store for the packaging industry in India and South Asia this coming year? Inflation, disruption of supply chains or environmental regulation? Or the resumption of high rural demand, continued investment and industry consolidation? Whatever happens, Packaging South Asia will be there, providing clarity and independent technical and business information in India and South Asia and around the world. We are a compact Indian organization bringing a window of fair and rigorous technical and business information that the industry can access this year and beyond. Please support us with your advertising and subscriptions, to keep us going and growing.

Thank you.


Please enter your comment!
Please enter your name here